OTCMKTS:RSPI

RespireRx Pharmaceuticals Stock Forecast, Price & News

$0.04
0.00 (0.00 %)
(As of 04/16/2021 12:00 AM ET)
Add
Compare
Today's Range
$0.03
Now: $0.04
$0.05
50-Day Range
$0.03
MA: $0.05
$0.07
52-Week Range
$0.01
Now: $0.04
$0.26
Volume724,392 shs
Average Volume1.51 million shs
Market Capitalization$2.82 million
P/E RatioN/A
Dividend YieldN/A
Beta0.43
RespireRx Pharmaceuticals Inc. engages in the discovery, development, and commercialization of pharmaceuticals for the treatment of neurological and psychiatric disorders. It has two drug platforms comprising ResolutionRx, a pharmaceutical cannabinoids platform, which includes dronabinol that acts upon the nervous system's endogenous cannabinoid receptors for use in refractory chemotherapy-induced nausea and vomiting, as well as for anorexia in patients with AIDS; and EndeavourRx, a neuromodulators platform that comprises AMPAkines program, including proprietary compounds that are positive allosteric modulators (PAMs) of alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptors to promote neuronal function, and GABAkines program, including proprietary compounds that are PAMs of GABAA receptors. The company's lead ampakine, CX1739, which has completed Phase II clinical studies for opioid-induced respiratory depression (RD), as well as for central sleep apnea. It is also developing CX717, CX1739, and CX1942 that have clinical application in the treatment of CNS-driven neurobehavioral and cognitive disorders, SCI, neurological diseases, and orphan indications. The company was formerly known as Cortex Pharmaceuticals, Inc. and changed its name to RespireRx Pharmaceuticals Inc. in December 2015. RespireRx Pharmaceuticals Inc. was incorporated in 1987 and is headquartered in Glen Rock, New Jersey.
RespireRx Pharmaceuticals logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolOTCMKTS:RSPI
CUSIPN/A
Phone201-444-4947
Employees2
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value($1.79) per share

Profitability

Net Income$-2,120,000.00

Miscellaneous

Market Cap$2.82 million
Next Earnings Date5/19/2021 (Estimated)
OptionableNot Optionable

Headlines

News for RespireRx Pharmaceuticals Inc
December 10, 2020 |  markets.businessinsider.com
RespireRx Pharmaceuticals Inc
May 21, 2020 |  www.bloomberg.com
RespireRx Pharmaceuticals Inc.
May 20, 2020 |  www.barrons.com
See More Headlines

MarketRank

Overall MarketRank

0.48 out of 5 stars

Medical Sector

1640th out of 2,025 stocks

Pharmaceutical Preparations Industry

683rd out of 772 stocks

Analyst Opinion: 0.0Community Rank: 2.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
$0.04
0.00 (0.00 %)
(As of 04/16/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive RSPI News and Ratings via Email

Sign-up to receive the latest news and ratings for RSPI and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











RespireRx Pharmaceuticals (OTCMKTS:RSPI) Frequently Asked Questions

What stocks does MarketBeat like better than RespireRx Pharmaceuticals?

Wall Street analysts have given RespireRx Pharmaceuticals a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but RespireRx Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting RespireRx Pharmaceuticals?

RespireRx Pharmaceuticals saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 23,200 shares, an increase of 1,446.7% from the February 28th total of 1,500 shares. Based on an average trading volume of 3,215,500 shares, the short-interest ratio is currently 0.0 days.
View RespireRx Pharmaceuticals' Short Interest
.

When is RespireRx Pharmaceuticals' next earnings date?

RespireRx Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, May 19th 2021.
View our earnings forecast for RespireRx Pharmaceuticals
.

How were RespireRx Pharmaceuticals' earnings last quarter?

RespireRx Pharmaceuticals Inc. (OTCMKTS:RSPI) issued its quarterly earnings data on Wednesday, August, 19th. The company reported ($0.01) earnings per share (EPS) for the quarter.
View RespireRx Pharmaceuticals' earnings history
.

How has RespireRx Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

RespireRx Pharmaceuticals' stock was trading at $0.0330 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, RSPI shares have increased by 12.8% and is now trading at $0.0372.
View which stocks have been most impacted by COVID-19
.

Who are RespireRx Pharmaceuticals' key executives?

RespireRx Pharmaceuticals' management team includes the following people:
  • Dr. Arnold S. Lippa, Exec. Chairman & Chief Scientific Officer (Age 74, Pay $339.6k)
  • Dr. Jeff Eliot Margolis, Sr. VP, CFO, Treasurer, Sec. & Director (Age 65, Pay $321.6k)
  • Mr. Richard D. Purcell, Sr. VP of R&D (Age 60, Pay $199.86k)
  • Mr. Timothy L. Jones, Pres, CEO & Director (Age 48)
  • Mr. David Dickason, Sr. VP of Pre-Clinical Product Devel. (Age 58)
  • Mr. Marc M. Radin, Controller
  • Dr. Arvid Carlsson, Consultant (Age 98)

Who are some of RespireRx Pharmaceuticals' key competitors?

What other stocks do shareholders of RespireRx Pharmaceuticals own?

What is RespireRx Pharmaceuticals' stock symbol?

RespireRx Pharmaceuticals trades on the OTCMKTS under the ticker symbol "RSPI."

How do I buy shares of RespireRx Pharmaceuticals?

Shares of RSPI can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is RespireRx Pharmaceuticals' stock price today?

One share of RSPI stock can currently be purchased for approximately $0.04.

How much money does RespireRx Pharmaceuticals make?

RespireRx Pharmaceuticals has a market capitalization of $2.82 million.

How many employees does RespireRx Pharmaceuticals have?

RespireRx Pharmaceuticals employs 2 workers across the globe.

What is RespireRx Pharmaceuticals' official website?

The official website for RespireRx Pharmaceuticals is www.respirerx.com.

Where are RespireRx Pharmaceuticals' headquarters?

RespireRx Pharmaceuticals is headquartered at 126 VALLEY ROAD SUITE C, GLEN ROCK NJ, 07452.

How can I contact RespireRx Pharmaceuticals?

RespireRx Pharmaceuticals' mailing address is 126 VALLEY ROAD SUITE C, GLEN ROCK NJ, 07452. The company can be reached via phone at 201-444-4947 or via email at [email protected]


This page was last updated on 4/17/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security. Learn more.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.